ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

IMM Immupharma Plc

2.125
-0.055 (-2.52%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma Plc LSE:IMM London Ordinary Share GB0033711010 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.055 -2.52% 2.125 2.05 2.20 2.25 2.10 2.20 2,365,381 16:35:02
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Finance Services 0 -3.81M -0.0114 -1.89 7.17M
Immupharma Plc is listed in the Finance Services sector of the London Stock Exchange with ticker IMM. The last closing price for Immupharma was 2.18p. Over the last year, Immupharma shares have traded in a share price range of 0.83p to 3.78p.

Immupharma currently has 333,403,115 shares in issue. The market capitalisation of Immupharma is £7.17 million. Immupharma has a price to earnings ratio (PE ratio) of -1.89.

Immupharma Share Discussion Threads

Showing 7451 to 7472 of 39125 messages
Chat Pages: Latest  305  304  303  302  301  300  299  298  297  296  295  294  Older
DateSubjectAuthorDiscuss
15/12/2017
11:03
Stephen2010. Your spam-tastic :)
hamhamham1
15/12/2017
10:58
As I posted yesterday evening. Check out ALBA. Huge multibag potential.

ALBA currently trading at 0.39p target price 6p making a nice 15 bagger. Please read the following:

MARKET CAP PUZZLE
❖ Alba (market cap £8.4m) is in a resources neighbourhood populated with listed
companies with much enhanced market capitalisations, such as UKOG.L (£134m) and
JAY.L (£172m). With either shared project interests or adjacent tenements to these
companies, Alba should trade at a much higher valuation than its current token value.
Like Bluejay, Alba owns 100% of its ilmenite project. Direct comparisons with UKOG
are also instructive. While both companies own other projects, UKOG’s 49.9% of Horse
Hill Developments Limited (HHDL), when compared to Alba’s 18.1% means that Alba
has approximately one third of the value of Horse Hill compared to UKOG but only
about 7% of the market capitalisation. Once the market recognises these disparities,
the room for growth in Alba’s share price is undeniable.

VALUATION RATIONALE - Our valuation in this First Equity Limited initiation note
uses a risked valuation approach for Alba’s two main projects, at Horse Hill and TBS. The
Horse Hill licences are valued using independent published technical data from
Schlumberger, Xodus and Nutech on the oil potential of the licences, along with our own
assumptions on recovery rates, oil discovery value, resource and development risks
factors. From this a risked value of $127m net to Alba on a ‘Base Case’ basis is derived
for Horse Hill.

Given the similar geology and economic potential of both TBS and Dundas, we have
adopted a risked closeology valuation approach, by computing an NPV for Dundas of
$223m and then applying a three-tiered risked probability calculation to arrive at a value
of $54.7m for TBS. Once Alba announce its JORC resource and exploration target at TBS
and Bluejay its Feasibility Study results, this number is likely to be revised upwards very
rapidly, possibly up to $200m, representing up to 7p per share in additional shareholder
value.

We compute a valuation of $185m (£139m) for Alba, equating to 6.0p per share, of which
4.1p is attributed to the stake in Horse Hill, 1.8p for TBS. Given this analysis and wealth
of valuation catalysts anticipated across the project portfolio in the coming months, we
recommend the shares as a ‘BUY, with a Target Price of 6.0p, representing a potential
15 times plus uplift from the current share price.

stephen2010
15/12/2017
09:45
MM’s ready to mug anymore festive sellers, most have probably worked out not to sell one bring this close to potentially huge game changing news for IMM

If majority of buyers are holding, the stock shortage will become more apparent and the share price will keep rising. It’s following a similar pattern after previous leg ups.

ny boy
15/12/2017
09:31
premuims being paid for anything 5k up
sportbilly1976
15/12/2017
08:10
It works alright.
top tips
15/12/2017
08:03
8p spread Lol
herschel k
15/12/2017
08:00
"I am only putting enough on here that, if lost, wouldn't be any trouble""

Sensible approach with any company's shares these days!!

gbh2
14/12/2017
21:58
A good investment advice i.e. "... as much as I like the share, I am still keeping it in perspective (financially). I am only putting enough on here that, if lost, wouldn't be any trouble"
ashehzi
14/12/2017
21:47
Thanks mate
jp1962
14/12/2017
21:39
Probably more like end of January I reckoned but it’s all a guess really, only IMM will know, maybe the share price will give us clues also, always leaky leaky on a major event.

Not long to wait only 27 trading days to go now!

ny boy
14/12/2017
20:56
Are the results likely to come out in jan
jp1962
14/12/2017
20:49
But as much as I like the share, I am still keeping it in perspective (financially). I am only putting enough on here that, if lost, wouldn't be any trouble.
hamhamham1
14/12/2017
20:01
Yep I totally agree. Without the knowledge of P3 results and any subsequent FDA approval then this is a different kettle of fish. So there are lots of reasons at this point for IMM to be valued substantially less. Lets face it, its a gamble, but I'm basing my gamble on the results to date, Benlysta's path cutting (first new Lupus drug in 50 years) and the P140 innovative platform (blocking transmission above the T cell rather than blasting the low level B cells). That is if I understand the approach :)
hamhamham1
14/12/2017
19:55
Will gsk buy this
stevenrevell
14/12/2017
19:50
Yes, hamhamham, but what was the market capital of HGS the day before its P3 read out, and then on FDA approval, and then on the GSK buyout?
divmad
14/12/2017
19:10
When Human Genome Sciences, HGS (who jointly developed Benlysta with GSK) was bought out by GSK (both companies having a 50% stake each in Benlysta). HGS market capital was valued at about $1.8bn the day before the buyout offer, then the offer (offer equiv to $3.6bn) this was at a 99% premium to the previous days closing price. So a regular days market price is one thing, then the next day if someone wants to buy you out well then that's another thing altogether.
hamhamham1
14/12/2017
19:09
IMM Immupharma....... a look at the' feet on the ground'

hxxp://www.epo.org/learning-events/european-inventor/finalists/2017/muller.html

3rd eye
14/12/2017
18:58
The target given by a recent broker is £9 if successful so £16 seems a tad rich!
jp1962
14/12/2017
18:53
Anyone who can afford to never work again if a share is a 10 bagger must have a pretty large stake in that company imo
spawny100
14/12/2017
18:49
Come on 10 bagger! You sure lol.I wish as I would never have to work again if that was the case!
jp1962
14/12/2017
18:45
Positive results = 10 bagger it's as simple as that.. I keep looking for other stocks maybe to top slice my overweight position here. can't find anything like it.
blackbear
14/12/2017
17:09
Exactly spawny. If news is good no chance im selling anything before any deal is announced
immy1992
Chat Pages: Latest  305  304  303  302  301  300  299  298  297  296  295  294  Older

Your Recent History

Delayed Upgrade Clock